Synonym
LY 165163; LY165163; LY-165163; LY 165,163; LY165,163; LY-165,163.
IUPAC/Chemical Name
Benzenamine, 4-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-
InChi Key
GAAKALASJNGQKD-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H22F3N3/c20-19(21,22)16-2-1-3-18(14-16)25-12-10-24(11-13-25)9-8-15-4-6-17(23)7-5-15/h1-7,14H,8-13,23H2
SMILES Code
NC1=CC=C(CCN2CCN(C3=CC=CC(C(F)(F)F)=C3)CC2)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
349.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fuller RW, Snoddy HD, Molloy BB. Central serotonin agonist actions of LY 165163, 1-(m-trifluoromethylphenyl)-4-(p-aminophenylethyl) piperazine, in rats. J Pharmacol Exp Ther. 1986 Nov;239(2):454-9. PMID: 2430093.
2: Hutson PH, Donohoe TP, Curzon G. Neurochemical and behavioural evidence for an agonist action of 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine (LY 165163) at central 5-HT receptors. Eur J Pharmacol. 1987 Jun 19;138(2):215-23. doi: 10.1016/0014-2999(87)90435-3. PMID: 3113985.
3: Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987;1(1):3-9. doi: 10.1002/syn.890010103. PMID: 3505364.
4: Millan MJ, Rivet JM, Audinot V, Gobert A, Lejeune F, Brocco M, Newman- Tancredi A, Maurel-Remy S, Bervoets K. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. J Pharmacol Exp Ther. 1995 Jun;273(3):1418-27. PMID: 7791116.
5: Sprouse JS, Aghajanian GK. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology. 1988 Jul;27(7):707-15. doi: 10.1016/0028-3908(88)90079-2. PMID: 2901680.
6: Millan MJ, Bervoets K, Mavridis M. The serotonin (5-HT)1A agonist, LY 165,163, induces contralateral rotation in unilateral substantia nigra-lesioned rats via dopamine receptors. Neurosci Lett. 1991 Sep 16;130(2):173-6. doi: 10.1016/0304-3940(91)90390-f. PMID: 1795876.
7: Asarch KB, Ransom RW, Shih JC. 5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity. Life Sci. 1985 Apr 1;36(13):1265-73. doi: 10.1016/0024-3205(85)90271-1. PMID: 3982214.
8: Schoeffter P, Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br J Pharmacol. 1988 Nov;95(3):975-85. doi: 10.1111/j.1476-5381.1988.tb11728.x. PMID: 3207999; PMCID: PMC1854240.
9: Millan MJ, Rivet JM, Gobert A, Canton H, Veiga S, Bervoets K. 5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm. J Pharmacol Exp Ther. 1994 Apr;269(1):121-31. PMID: 7909555.
10: Takeuchi Y, Yang W, Shih JC. Identification of 5-hydroxytryptamine1A receptor proteins in bovine frontal cortex. J Neurochem. 1988 Nov;51(5):1343-9. doi: 10.1111/j.1471-4159.1988.tb01095.x. PMID: 3171582.
